1. Home
  2. QDEL vs XOMAO Comparison

QDEL vs XOMAO Comparison

Compare QDEL & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$28.59

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo AGNC Investment Corp.

XOMAO

AGNC Investment Corp.

N/A

Current Price

$25.53

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QDEL
XOMAO
Founded
1979
N/A
Country
United States
United States
Employees
N/A
13
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QDEL
XOMAO
Price
$28.59
$25.53
Analyst Decision
Hold
Analyst Count
6
0
Target Price
$39.33
N/A
AVG Volume (30 Days)
1.0M
N/A
Earning Date
02-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,714,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.50
N/A
52 Week High
$49.45
N/A

Technical Indicators

Market Signals
Indicator
QDEL
XOMAO
Relative Strength Index (RSI) 55.25 52.92
Support Level $28.22 $25.36
Resistance Level $29.94 $25.63
Average True Range (ATR) 1.26 0.19
MACD 0.06 0.01
Stochastic Oscillator 54.71 87.49

Price Performance

Historical Comparison
QDEL
XOMAO

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

About XOMAO AGNC Investment Corp.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: